Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Study identifier: NCT01576172
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


  • Progressive metastatic hormone-resistant prostate cancer
  • On androgen-deprivation therapy
  • Willing to undergo biopsy of metastatic lesion or have adequate archival metastatic tissue which can be used for ETS fusion status
  • Patients can have up to 2 prior treatments
  • Patients with CNS metastasis are ineligible

Type of study:

Phase II

Patients will be randomized to two arms:

  • Patients in Arm 1 receive abiraterone acetate and prednisone on days 1-28
  • Patients in Arm 2 receive veliparib on days 1-28, as well as abiraterone acetate and prednisone beginning on day 8 of course 1 and day 1 of course 2 and all subsequent courses.

Study site:

University of Chicago
Contact: Walter M. Stadler 773-702-4150

Evanston CCOP-NorthShore University HealthSystem
Contact: Daniel H. Shevrin 847-570-2515

Indiana University Medical Center
Contact: Noah M. Hahn 317-948-1186

Johns Hopkins University
Contact: Emmanuel S. Antonarakis 410-502-7528

Ann Arbor
University of Michigan University Hospital
Contact: Maha H. Hussain 734-936-8906

North Carolina
Chapel Hill
University of North Carolina Recruiting
Contact: Young E. Whang 919-843-9983


Page updated 06/10/13

FORCE:Facing Our Risk of Cancer Empowered